tumor specific prodrug of TGFβR inhibitor
QW dosing, improved tumor-to-heart ratio
BMS-986260 prodrug w/ self-immolative link.
Journal of Medicinal Chemistry
Bristol Myers Squibb, Princeton, NJ
The BMS TGFβR inhibitor prodrug, “compound 10,” demonstrates antitumor efficacy comparable to the parent compound (BMS-986260) in a syngeneic model with once-weekly dosing, while reducing the systemic exposure of…